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Abstract  Understanding the mechanisms of steroidogenic regulation in female fertility is fundamental to 
determining dysfunction. Research has revealed a strong relationship between fertility and metabolic disturbances. 
With many endocrine signals involved in activation of steroidogenic cascades, it has become necessary to map the 
complex cross-talk between these regulatory systems and this review looks to establish this based on current 
understanding. Luteininsing hormone is a vital endocrine hormone that is already known to signal via these 
pathways, although its involvement in metabolic disturbance is less understood. Studies investigating activation of 
the LH receptor in key steroidogenic cells, ovarian theca and granulosa, have highlighted overlaps in important 
signaling cascades including PKC/MAPK/PKA and PI3K. Here, we review LH and its signaling cross-talk in key 
steroidogenic pathways. 
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1. Introduction 
The pituitary gland is responsible for secretion of 
various endocrine signalling hormones with the anterior 
pituitary producing somatotrophins, thyrotrophins, 
corticotrophins, lactotrophins and gonadotrophins. 
Dysfunction of the pituitary gland can therefore have 
systemic effects as a result of signalling errors and 
conditions such as hyper and hypopituitarism. These 
dysfunctions have been linked to the pathophysiology of 
conditions such as diabetes and the metabolic syndrome. 
There has been a rapid increase in diabetes mellitus (DM) 
over the past decades resulting in it becoming one of the 
most prevalent endocrine disorders, effecting ~135 million 
people. Therefore, it is vital to understand the mechanisms 
behind the condition [1,2]. 
Many studies have examined the effect of diabetes on 
gonadotropin production with an aim of determining a 
relationship between impaired fertility and menstrual 
disturbances [3,4,5]. In doing so, the importance of 
luteinising hormone (LH) in pituitary regulation has been 
highlighted, as well as its sensitivity to metabolic changes 
[1]. Although reduced gonadotropin response may play 
only a partial role in steroidogenic function it is important 
to understand the mechanism and pathways involved in 
order to fully understand the overall dysfunction. 
This review will examine our current understanding of 
the effects of LH on steroidogenic cells to allow future 
mapping of possible regulatory pathways that may be seen 
as targets for dysfunction in metabolic diseases. 
2. Luteinising Hormone and 
Steroidogenesis 
The gonadotropins are a family of proteins consisting of 
LH, follicular stimulating hormone (FSH) and the 
chorionic gonadotropins (CG). These hormones are vital 
in the control and regulation of reproductive function in 
males and females. LH and FSH are secreted by the 
anterior pituitary gland, whereas CG is produced by a 
component of the fertilised egg called the syncytiotrophoblast. 
LH, also known as lutropin, stimulates ovulation and 
development of the corpus lutea in females. Structurally 
LH is a heterodimeric glycoprotein similar in structure to 
FSH, thyroid stimulating hormone and human chorionic 
gonadotropin (hCG). All four proteins share a common 
alpha subunit, with the beta subunits conferring biological 
specificity [6,7].  
In females, FSH action on ovarian granulosa cells 
initiates follicular growth. This stimulates a rise in 
estrogen and LH receptor expression. Eventual positive 
feedback to the hypothalamus occurs, resulting in the 
release of LH over a 24 - 48hr period. The ensuing LH 
surge triggers ovulation, releasing the egg and initiating 
the production of the corpus luteum from the remnants of 
the follicle. The corpus luteum secretes progesterone for 
endometrial preparation and the possibility of implantation.  
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LH is maintained for up to two weeks allowing for 
steroidogenesis along with support via hCG action. In the 
case of pregnancy LH supports thecal cells which produce 
androgens necessary for estradiol synthesis and cell 
proliferation [3,7]. 
3. LH Receptor 
Luteinising hormone / chorionic gonadotropin activates 
multiple signal transduction systems. The luteinising 
hormone receptor is part of the glycoprotein hormone 
receptor family (GpHRs) which also includes follicular 
stimulating hormone receptor (FSHR) and thyroid 
stimulating hormone receptor (TSHR). The LH receptor 
differs from these through its ability to bind two 
glycoprotein hormones, LH and hCG. These receptors are 
responsible for regulation of reproductive and metabolic 
processes with LHR activation leading to androgen 
synthesis and ovulation. The GpHRs contain two major 
domains of approximately the same size. Firstly, a large, 
glycosylated N-terminal ectodomain (ECD) containing 
leucine-rich repeats (LRRs) capped by cys-rich regions, 
the latter forming a portion of a hinge region. Secondly, a 
trans-membrane domain (TM) with seven membrane 
spanning helices, three extracellular loops (ecls), three 
intracellular loops (icls) and a short icl 4, an eighth 
cytoplasmic helix parallel to the plasma membrane, and a 
cytoplasmic tail [3]. The ECD and TM domains have 
important and distinct functional roles, namely hormone 
binding and signal transduction, respectively [8,9]. 
Most of the sequential steps involved after hormone 
binding to the ECD until G protein activation on the inner 
face of the plasma membrane remain poorly understood. In 
many experimental systems, LH or hCG binding to LHR 
results in activation of both protein kinase A and protein 
kinase C. At relatively low concentrations of LH and hCG, 
Gs appears to be the preferred signalling pathway, 
resulting in a rapid increase in the intracellular 
concentration of cAMP [10].  
4. Cyclic Adeno Monophosphate 
cAMP is derived from adenosine triphosphate and is 
utilised within intracellular signal transductions as a 
second messenger, transferring the effects of hormones 
incapable of permeating cellular membranes. Typically, it 
allows activation of protein kinases and is also involved in 
the release of intracellular calcium from the endoplastic 
reticulum. 
cAMP synthesis occurs through adenlyl cyclase action 
on ATP located on the inner plasma membrane and 
decomposition occurs through phosphodiesterase action 
on cAMP. This action occurs through stimulatory G-protein 
(Gs)-coupled receptor activation and is inhibited by agonists 
of adenylyl cyclase inhibitory G (Gi)-protein-coupled 
receptors.  
Adenylate cyclase can be activated or inhibited by G 
proteins, which are coupled to membrane receptors and 
thus can respond to hormonal or other stimuli. Following 
activation cAMP acts as a second messenger by 
interacting with and regulating other proteins such as 
protein kinase A and cyclic nucleotide-gated ion channels 
[11,12].  
Studies in pre-pubertal female rats have shown that in 
conditions such as uraemia can lead to reduced 
gonadtropin - cAMP sensitivity. This condition is related 
to metabolic disturbance and has direct associations to 
diabetes mellitus and diabetes induced cardiac failure as 
well as chronic kidney failure [13]. Furthermore, female 
uremic patients have shown menstrual irregularities and 
cases of delayed puberty possibly associated with 
gonadotropin target response. However, research in 
uremic premenopausal women has also shown hormonal 
disturbances including an absence in pre-ovulatory peaks 
of LH and estradiol concentrations. The source of these 
irregularities may therefore originate within the 
hypothalamus via impaired production of GnRH or in the 
anterior pituitary rather than within the cellular targets 
[14].  
5. Diacylglycerol/Protein Kinase C 
Pathway 
Diacylglycerol (DAG) is a key second messenger that 
regulates important cellular responses including 
proliferation, apoptosis, immune response and 
differentiation. This occurs via its target protein protein 
kinase C (PKC). Activation is linked to the LH receptor as 
a hepta-membrane spanning protein that couples 
stimulatory binding proteins Gs and Gq to allow adenylate 
cyclise signalling and increases in cAMP. This 
subsequently activates cAMP dependent PKA [11,15].  
LH receptor activation increases intracellular calcium 
as a result of phospholipase C activation (PLC) [5,16]. 
Once activated PLC allows cleavage of phosphatidylinsitol, 
4, 5-biphospate into inositol 1, 4, 5 triphosphate (IP3) and 
diacyglycerol (DAG). IP3 then binds to intracellular 
calcium channels on the endoplasmic reticulum resulting 
in increased cytosolic calcium levels. DAG binds to 
protein kinase C (PKC) allowing co-activation (see  
Figure 1) [17,18]. PKC requires calcium, phosphatitylserine 
and DAG for activation. These regulators allow a 
conformational change revealing the substrate binding site 
[19].  
 
Figure 1. PKC pathway showing crosstalk between glucose and LH 
activation 
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Mitogen activating protein kinase (MAPK) activation 
has been found to be independent of PKC activation in 
ovarian granulosa cells. This suggests an independent 
pathway that may be regulated by LH alone. Furthermore, 
PKC has been seen to be partially activated by glucose 
and GAP in the absence of LH receptor activation in 
granulosa cells which may allow for pathway cross talk 
[20].  
6. MAPK Pathway 
Ras proteins are ubiqtous GTPases located on the inner 
surface of plasma membranes. They communicate 
receptor-mediated signal transduction pathways, 
transmitting extracellular signals that promote growth, 
proliferation, and differentiation. The signalling cascade 
starts from the plasma membrane where the growth factor 
binds to its enzyme-linked receptor. Receptor-linked 
tyrosine kinases such as the epidermal growth factor 
receptor (EGFR) are activated by extracellular ligands and 
binding of EGF’s. This leads to phosphorylation of the 
intracellular parts of the receptors. Activating guanine 
exchange factors (GEFs), such as SOS and GEFs allow 
the exchange of GDP to GTP activating Ras [21]. The 
major downstream target of Ras-GTP is mitogen-activated 
protein kinase (MAPK), but also activates 
phosphatidylinositol 3-kinase (PI3-kinase), Ras-related 
guanine nucleotide dissociation stimulator (RalGDS). 
Activation of MAPK occurs through specific 
phosphorylation of Raf, which is activated on the plasma 
membrane by Ras-GTP. Raf phosphorylates mitogen-
activated kinase 1/2 (MEK1/2 kinase), in turn activating 
the extracellular regulated kinase 1/2 (ERK1/2 kinase or 
p44/42 MAPK) by phosphorylation.  
The second class of enzymes in the ERK cascade are 
the MItogen-activated protein kinases (MEKs). These 
phosphorylate threonine and tyrosine residues. MEK1 and 
MEK2 are involved in ERK signalling and activated via 
there only substrate, Raf kinases. Inactivation of the ERKs 
can occur through de-phosphorylation via serine threonine 
or tyrosine phosphatases [22,23]. 
ERK1/2 kinase phosphorylates a variety of downstream 
targets, which results in changes in gene expression and 
the catalytic activities of enzymes and make them 
important targets in steroidogenic activity [24].  
A recent study showed that both MAPK kinase 
(MEK1/2) phosphorylation and extracellular signal related 
kinase (ERK1/2) phosphorylation were reduced by 50% in 
Polycystic ovarian syndrome (PCOS) steroidogenic cells 
compared with that in normal cells. A reduction in 
MEK1/2 and ERK1/2 phosphorylation is associated with 
increased thecal CYP17 gene expression and subsequent 
androgen biosynthesis [25].  
Treatment of ovarian steroidogenic theca cells with the 
MEK inhibitor PD98059 has been shown to augment 
thecal CYP17 gene expression and androgen biosynthesis 
[25]. The extent to which the other components of the 
MAPK pathway contribute to overall androgen biosynthesis 
requires further examination.  
Although LH has been reported to activate the 
cAMP/PKA pathway and the ERK/MAPK pathway in 
theca cells, whether and how LH stimulates the PI3K/Akt 
cascade in theca cells remains unclear. Recent studies 
have shown LH stimulates Akt phosphorylation in both 
cultured bovine and human theca cells, and that activation 
of PI3K/Akt is involved in CYP17A1 mRNA expression 
and androgen production in theca cells thus supporting LH 
activation of PI3K [26,27,28]. H89, a potent and selective 
inhibitor of PKA, did not affect LH-mediated changes  
in phospho-Akt, indicating that a pathway distinct  
from that of the PKA is involved in LH-induced Akt 
phosphorylation in theca cells.  
In contrast to PKA inhibitor, the MEK inhibitor (U0126) 
blocked LH-mediated Akt phosphorylation and androgen 
production in theca cells. This suggests that LH stimulates 
CYP17A1 mRNA expression and androgen production in 
theca cells via activation of the PI3K/Akt pathway and 
with the involvement of the MAPK pathway.  
While the precise mechanism for the activation of PI3K 
pathway by LH in theca cells is not known, we propose 
LH-induced phospho-Akt up-regulation may involve 
MAPK-mediated down-regulation of phosphatase and 
tensin homologue (PTEN) a tumour suppressor which 
negatively regulates Akt phosphorylation. In this context, 
it has been shown that PI3K is required for estradiol-
stimulated hepatic cell growth and that the MAPK 
pathway reduces the level of PTEN, allowing estradiol-
induced phosphorylation of Akt [29]. Whether this indeed 
is the case in the theca cells awaits further investigation. 
7. Discussion 
Clarification of the LH-mediated intracellular signalling 
events is essential along with consideration for cross talk 
and compensatory mechanisms between pathways. This will 
allow for better understanding of not only ovarian physiology, 
but also of the pathophysiology of steroidogenic dysfunction. 
Studies in ovarian steroidogenic granulosa cells have 
shown elevated cAMP and activated ERK. PKA forms 
inactive RAP1 inhibiting RAF1 and preventing MEK 
phosphorylation of ERK and subsequent androgen 
synthesis [30]. Based on these findings increased cAMP 
may allow phosphorylation of cAMP-responsive guanine 
nucleotide exchange factors (Epac1 and Epac2). Upon 
binding of cAMP, Epac1/2 may rapidly activate Rap1, 
which subsequently promotes activation of B-raf and the 
rest of the ERK cascade [31]. 
Direct activation by cAMP, RAP1 and subsequent 
BRAF activation would lead to MEK phosphorylation 
(LH mediated androgen synthesis). Inhibition of PKA 
would prevent RAP1 formation and eventual RAF1 
inhibition would return due to reduced RAP1 formation 
(see Figure 2). This is supported by studies showing LH 
mediated ERK phosphorylation only occurring within 
24hrs of LH exposure during PKA inhibition [32]. 
With the importance of steroidogenic regulation in 
fertility and our understanding of the relationship this may 
have with metabolic dysfunction, it is important to 
understand cross talk within regulatory pathways and the 
involvement of hormonal regulators. LH continues to 
show a vital role in multiple signalling cascades and its 
specific involvement requires further examination. 
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Figure 2. Proposed signal cascade / crosstalk in steroidogenesis, 
following LH and EGF activation 
In summary greater understanding of the multiple functions 
of LH in hormone synthesis is beginning to immerge with 
the increased mapping of the pathways involved. As we 
have suggested here, It is becoming more apparent that 
cross talk across pathways is likely as a compensatory 
method in accommodating steroidogenesis as more research 
shows how dysfunction in steroidogenic function leads to 
alternate hormone/protein involvement and production. The 
research discussed here therefore suggests further examination 
of these noted steroidogenic pathways and their possible 
crosstalk would be beneficial in future examinations of 
conditions relating to steroidogenic dysfunction. 
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